Association of metformin, dipeptidyl dipeptidase-4 inhibitors, and insulin with COVID-19-related hospital outcomes in patients with type 2 diabetes
BS Derrick Obiri-Yeboah, MS James Bena, MD Mahmoud Alwakeel, MD, MPH Lauren Buehler, MD, FACE Vinni Makin, MD Keren Zhou, DO, FACE, M Kevin M Pantalone, MD, MPH M Cecilia Lansang
Endocrine Practice, doi:10.1016/j.eprac.2023.06.001
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
Bassendine, Bridge, Mccaughan, Gorrell, COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?, J Diabetes,
doi:10.1111/1753-0407.13052Chen, Yang, Cheng, Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication, Diabetes Care,
doi:10.2337/dc20-0660Crouse, Grimes, Li, Might, Ovalle et al., Metformin use is associated with reduced mortality in a diverse population with covid-19 and diabetes, Frontiers in Endocrinology,
doi:10.3389/fendo.2020.600439Han, Ma, Sun, Association between anti-diabetic agents and clinical outcomes of COVID-19 in patients with diabetes: A systematic review and meta-analysis, Arch Med Res,
doi:10.1016/j.arcmed.2021.08.002Jehi, Ji, Milinovich, Individualizing Risk Prediction for Positive Coronavirus Disease 2019 Testing, Chest
Khunti, Knighton, Zaccardi, Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England, The Lancet Diabetes & Endocrinology,
doi:10.1016/S2213-8587Li, Wei, Li, Metformin use in diabetes prior to hospitalization: effects on mortality in Covid-19, Endocrine Practice,
doi:10.4158/EP-2020-0466Luo, Qiu, Liu, Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis, Am J Trop Med Hyg,
doi:10.4269/ajtmh.20-0375Mirani, Favacchio, Carrone, Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with COVID-19: A case series from an academic hospital in Lombardy, Italy. Diabetes Care,
doi:10.2337/dc20-1340Nauck, Meier, Reduced COVID-19 mortality with sitagliptin Treatment? Weighing the dissemination of potentially lifesaving findings against the assurance of high scientific standards, Diabetes Care,
doi:10.2337/dci20-0062Prattichizzo, De Candia, Nicolucci, Ceriello, Elevated HbA1c levels in pre-Covid-19 infection increases the risk of mortality: A sistematic review and meta-analysis, Diabetes Metab Res Rev,
doi:10.1002/dmrr.3476Solerte, 'addio, Trevisan, Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with Type 2 Diabetes and COVID-19: A multicenter, case-control, retrospective, observational Study, Diabetes Care,
doi:10.2337/dc20-1521Wander, Lowy, Beste, Prior glucose-lowering medication use and 30-day outcomes among 64,892 veterans with diabetes and COVID-19, Diabetes Care,
doi:10.2337/dc21-1351
